Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Philippe Marteau, Pia Munkholm et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic ResectionMiguel Regueiro, Pierre Desreumaux, Brian G. Feagan et al.|Gastroenterology|2016Cited by 329
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, Peter M. Irving et al.|The Lancet|2022Cited by 295
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical OutcomesBritt Christensen, David T. Rubin, Stephen B. Hanauer et al.|Clinical Gastroenterology and Hepatology|2017Cited by 234
Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel DiseaseFrank Hoentjen, Adriaan A. van Bodegraven, Margien L. Seinen et al.|Inflammatory Bowel Diseases|2012Cited by 102